Rebirthel Co., Ltd. was founded in October, 2019.
Rebirthel aims to realize cell-based therapies against cancer or other immune-related diseases by using universal
T cells that are regenerated from pluripotent stem cells.
The strategy is based on methods developed by myself, Dr. Hiroshi Kawamoto (Kyoto University).

It has been shown to be effective to transfuse genetically engineered T cells that had originally been collected from patients.
However, such “autologous” settings have faced problems: costly, time-consuming, and dependent on the quality of the T cells themselves (from the patients).
To solve these problems, Rebirthel provides “off-the-shelf T cells” that can be universally used with any patients in an allogeneic setting.

Pluripotent stem cells such as iPS (induced pluripotent stem) cells or ES (embryonic stem) cells have the potential to produce various types of tissues/organs.
Rebirthel has already established a method by which potent killer T cells can be produced in vitro from iPS cells.
Using this method, Rebirthel is now developing a strategy where tumor antigen-specific T cells are mass-produced and transfused to patients as off-the-shelf T cells.

Certain types of T cells play the role of commander of immune cells, while other types serve as strong warriors.
Therefore, if we can produce different types of T cells - such as killer T cells, helper T cells, or regulatory T cells - covering a wide range of target antigens, we can provide therapeutic T cells targeting any kind of disease related to the immune system (e.g. cancer, infectious diseases, autoimmune diseases, allergies, etc.).

Rebirthel opens the way to a future when patients go to hospital to receive transfusion of T cells to treat their disease.


Rebirthel Co., Ltd.
Room 311, Creation Core Kyoto Mikuruma, 448-5,
Kajii-cho, Kamigyo-ku, Kyoto 602-0841 Japan
Oct 1st, 2019
Capital stock
30,000,000 JPY
Hiroh Saji
Hiroshi Kawamoto
Development and operationalization of cell-based cancer immunotherapies

Business Summary

Rebirthel operationalizes cell-based cancer immunotherapies developed by Professor Hiroshi Kawamoto (Institute for Frontier Life and Medical Sciences, Kyoto University).
Rebirthel will provide “universal” cytotoxic T lymphocytes regenerated from pluripotent stem cells, to be used as “off-the-shelf T cells” in cancer immunotherapy.

Company history

January 2016
Regcell Co., Ltd. founded by Dr. Shimon Sakaguchi
April 2016
Hiroshi Kawamoto joined Regcell. Regcell aims to realize cell therapy using regulatory T cells or killer T cells.
May 2017
Regcell allocated new shares to third party and increased capital to 6,000,000 USD.
August 2017
Regcell allocated new shares to third party and increased capital to 200,000 USD.
October 2019
Rebirthel Co., Ltd. was founded by dividing Regcell into Regcell and Rebirthel.
Rebirthel took over all projects and intellectual properties related to killer T cells.
・Regcell raised 620,000,000 JPY through a third-party allocation of new shares.
・Regcell raised 20,000,000 JPY through a third-party allocation of new shares.


Rebirthel develop novel method for T cell therapy and provides “off-the-shelf T cells” against cancer.

(1) Killer T cells regenerated from HLA-matched iPS cells(1) Killer T cells regenerated from HLA-matched iPS cells

Transferred cells will immediately be rejected if the HLA haplotype does not match to that of the recipient.
In the regenerative medicine field, induced pluripotent stem (iPS) cells stock projects have been promoted where iPS cells that have been produced from healthy donors carrying the same HLA haplotype in both mother and father-derived alleles.
The cells/tissues regenerated from such iPS cells are expected to be transplanted to recipients who have the same HLA haplotype of at least one allele without inducing a severe rejection reaction.
At present, the most frequent four iPS cell lines are available from the Center for iPS Cell Research and Application (Kyoto University), covering 35% of the Japanese population.
We transduce these iPS cells with exogenous TCR and regenerate killer T cells from these iPSCs. Such regenerated T cells will be given to the patients in a HLA homo-to-hetero transfusion setting.

(2) Killer T cells regenerated from HLA-deleted iPS/ES cells(2) Killer T cells regenerated from HLA-deleted iPS/ES cells

When the HLA genes of iPS cells are deleted, cells/tissues regenerated from such HLA-null-iPS cells can be transplanted to any patient.
This strategy can be applied not only for iPS cells but also for ES cells.


OP9 cell line and its genetically modified derivatives

Rebirthel has succeeded all rights of the OP9 cells from Dr. Hiroaki Kodama (who originally established the OP9 cell line).
You are required to obtain a license from Rebirthel for commercial use of the OP9 cell line or its derivatives.

OP9 cells


NEWS 2021.6.23 Exhibiting at Arab Health 2021

Professor Hiroshi Kawamoto’s laboratory, Kyoto University, is now making an exhibition of its research activity with a booth at Arab Health 2021, held in Dubai, UAE from June 21st to June 24th 2021. T...

NEWS 2021.6.8 Our research activity to develop a new T cell therapy for COVID-19 was introduced in the TV program “Hodo Station”

Professor Hiroshi Kawamoto, a director of Rebirthel and the Vice Director of Institute for Frontier Life and Medical Sciences, Kyoto University, appeared on the TV program “Hodo Station” presented by ...

NEWS 2021.5.15 Professor Hiroshi Kawamoto’s research was featured on Sankei Shimbun (Japanese newspaper)

In the evening edition of Sankei Shimbun on May 15th, 2021, Professor Hiroshi Kawamoto’s research activity was introduced. The article entitled “Fast-growing university ventures” occupies a large spac...

NEWS 2021.3.4 The article introducing Rebirthel was published in the web magazine “Nikkei Biotechnology & Business”

Nikkei Biotechnology & Business is the leading news site of biotechnology in Japan. In its recent issue, Rebirthel is introduced. In the article, TCR-iPS cell method and DP method which are our pa...

NEWS 2020.12.11 Our R&D activity to develop a new T cell therapy for the novel coronavirus infection was introduced on Japanese TV program.

Professor Hiroshi Kawamoto, an excecutive director of Rebirthel, is recently conducting the collaborative research to develop a new therapy for the novel coronavirus infection with Fujita Health Unive...

NEWS 2020.10.15 Collaborative research project between Rebirthel and Fujita Health University – On-side visit video

This video was taken when our executive director, Hiroshi Kawamoto (Professor, Institute for Frontier Life and Medical Sciences, Kyoto University) visited Fujita Health University at the start of the ...

NEWS 2020.10.14 Rebirthel concluded the research collaboration agreement with Fujita Health University. – Joint development of the therapy for the novel coronavirus infection using universal killer T cells –

Rebirthel Co., Ltd. concluded an agreement to collaborate with Fujita Health University to develop a new therapy for novel coronavirus infection and entered into the contract. Killer T cells which are...

NEWS 2020.10.1 Rebirthel concluded the research license agreement with Otsuka Pharmaceutical.

Rebirthel Co., Ltd. (hereafter Rebirthel) concluded the research license agreement with Otsuka Pharmaceutical Co., Ltd. (hereafter OtsukaPharmaceutical) on October 1st 2020. Under this agreement, Rebi...

NEWS 2020.4.9 Introduction

The world is presently facing the serious situation of the coronavirus pandemic. We all need to work together on a global basis to end this crisis.Unfortunately, the pandemic does not decrease the inc...

See the list of NEWS


Privacy Policy

We will not use your personal information for any purpose other than contacting customers.
Please be sure to read our privacy policy.